How GLP-1 became the breakthrough multi-organ drug of the decade.
GLP-1 drugs have quickly moved beyond their image as “just weight-loss medicines.” Recent U.S. approvals, Zepbound (tirzepatide) for sleep apnea in 2024, Wegovy (semaglutide) for MASH with fibrosis in 2025, and Ozempic (semaglutide) for reducing the risk of kidney disease worsening, show how these medicines are now being used for a wide range of health […]